In multivariable models, LDLT recipients transplanted at experienced centers with autoimmune hepatitis or cholestatic liver disease had significantly less graft failure (HR: 0.56, 95% CI: 0.37-0.84 and HR: 0.76, 95% CI: 0.63-0.92, respectively), and increased patient survival. An LDLT risk score facilitated stratification of LDLT recipients into high, intermediate, and low-risk groups, with predicted 3-year graft survival ranging from >87% in the lowest risk group to <74% in the highest risk group. Conclusions: Current post-transplant outcomes for LDLT are equivalent, if not superior to DDLT when performed at experienced centers. An LDLT risk score can be used to

optimize LDLT outcomes and provides objective selection criteria for donor selection in LDLT. Disclosures: David S. Goldberg – Grant/Research Support: Bayer Healthcare Ensartinib supplier The following people have nothing to disclose: Benjamin French, PI3K inhibitor Peter L. Abt, Kim M. Olthoff, Abraham Shaked Backgrounds: Recurrence of hepatocellular carcinoma (HCC) is common after surgical resection. Anti-platelet therapy with aspirin and clopidogrel is recently revealed to prevent hepatic carcinogenesis. However, whether anti-platelet therapy also determines the prognoses of patients with HCC after resection surgery is still obscure. Aims: This population-based study aimed to investigate the association between anti-platelet treatment and the

outcomes in patients with hepatitis B virus (HBV)-related HCC after resection surgery. Method: By analyzing the data from Taiwan National Health Insurance Research Database, we identified 9,461 HBV-related HCC patients who underwent curative liver resection between January 1997

check details and December 2011. After one-to-four matching by sex, age and propensity score, 2,210 patients were enrolled for analyses. Kaplan-Meier method and modified Cox proportional hazard models were employed for survival and multivariable, strati- fied analyses. Results: The recurrence-free survival after 1, 5, 10 years of observation was significantly better in the treated cohort (84.62%, 46.80%, 28.30%) than untreated cohort (76.47%, 38.51%, 23.78%) (p = 0.021). Meanwhile, the 1-, 5-, 10-year overall survival in the treated cohort (96.96%, 80.29%, 57.30%) was also better than untreated cohort (92.28%, 62.47%, 45.50%) (p < 0.001). On the multivariable Cox regression analysis, anti-platelet therapy (HR, 0.73; 95% CI, 0.63–0.85; p < 0.001), statin use (HR, 0.66; 95% CI, 0.49–0.90; p = 0.008) and non-aspirin, non-steroidal anti-inflammatory drugs use (HR, 0.72; 95% CI, 0.62–0.83; p < 0.001) were independently related to lower risks of HCC recurrence or death. The multivariable stratified analyses showed significantly better survivals in most subgroups of patients. Conclusion: Use of aspirin and clopidogrel was associated with a better recurrence-free survival and overall survival among patients with HBV-related HCC after liver resection.